Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Trauner

Showing results (721-730 of 777) with videos related to

Pageof 78
Sort By:
Hepatology (Baltimore, Md.)|March 20, 2024
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?David E J Jones, Ulrich Beuers, Alan Bonder, et al.
Gut|March 3, 2025
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T<sub>H</sub>17 pathogenicity and transdifferentiationCi Zhu, Nicole Boucheron, Osamah Al-Rubaye, et al.
Developmental Cell|January 28, 2020
E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and RegenerationValentina C Sladky, Katja Knapp, Claudia Soratroi, et al.
Journal of Hepatology|September 28, 2025
Phase II INTEGRIS-PSC trial of bexotegrast, an α<sub>v</sub>β<sub>6</sub>/α<sub>v</sub>β<sub>1</sub> integrin inhibitor, in primary sclerosing cholangitisGideon M Hirschfield, Kris V Kowdley, Palak J Trivedi, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2025
Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosisLorenz Balcar, Malin Fromme, Naomi Kappe, et al.
JCI Insight|June 22, 2026
Crosstalk between CD8+ T cells and systemic bile acid metabolism shapes antiviral immunity and immunopathologyFelix Clemens Richter, Zsofia Keszei, Csilla Viczenczova, et al.
JHEP Reports : Innovation in Hepatology|February 8, 2024
Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progressionJulius W Jaeger, Annette Brandt, Wenfang Gui, et al.
Gut|February 7, 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosisRohit Loomba, Daniel Q Huang, Arun J Sanyal, et al.
Journal of Crohn'S & Colitis|December 14, 2024
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic SignaturesMohammed Nabil Quraishi, Jonathan Cheesbrough, Peter Rimmer, et al.
Immunity|December 1, 2019
Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell FunctionAlexander Lercher, Anannya Bhattacharya, Alexandra M Popa, et al.
Pageof 78

Showing results (721-730 of 777) with videos related to

Sort By:
Pageof 78
Hepatology (Baltimore, Md.)|March 20, 2024
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?David E J Jones, Ulrich Beuers, Alan Bonder, et al.
Gut|March 3, 2025
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T<sub>H</sub>17 pathogenicity and transdifferentiationCi Zhu, Nicole Boucheron, Osamah Al-Rubaye, et al.
Developmental Cell|January 28, 2020
E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and RegenerationValentina C Sladky, Katja Knapp, Claudia Soratroi, et al.
Journal of Hepatology|September 28, 2025
Phase II INTEGRIS-PSC trial of bexotegrast, an α<sub>v</sub>β<sub>6</sub>/α<sub>v</sub>β<sub>1</sub> integrin inhibitor, in primary sclerosing cholangitisGideon M Hirschfield, Kris V Kowdley, Palak J Trivedi, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2025
Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosisLorenz Balcar, Malin Fromme, Naomi Kappe, et al.
JCI Insight|June 22, 2026
Crosstalk between CD8+ T cells and systemic bile acid metabolism shapes antiviral immunity and immunopathologyFelix Clemens Richter, Zsofia Keszei, Csilla Viczenczova, et al.
JHEP Reports : Innovation in Hepatology|February 8, 2024
Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progressionJulius W Jaeger, Annette Brandt, Wenfang Gui, et al.
Gut|February 7, 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosisRohit Loomba, Daniel Q Huang, Arun J Sanyal, et al.
Journal of Crohn'S & Colitis|December 14, 2024
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic SignaturesMohammed Nabil Quraishi, Jonathan Cheesbrough, Peter Rimmer, et al.
Immunity|December 1, 2019
Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell FunctionAlexander Lercher, Anannya Bhattacharya, Alexandra M Popa, et al.
Pageof 78